Reversal drug for urgent surgery in people on Factor Xa blood thinners
Part of Blood & lymphatic, Heart & circulation clinical trials.
This Phase 3 study tests TAK-330, a reversal (blocking) medicine, to reduce bleeding risk during urgent surgery for adults taking Factor Xa inhibitors like rivaroxaban, apixaban, or edoxaban. It’s for situations where surgery can’t wait and doctors need a fast way to restore normal clotting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) and can sign consent (or your legal representative can).
- You’re currently taking a Factor Xa blood thinner by mouth (rivaroxaban, apixaban, or edoxaban).
- You need urgent surgery within 15 hours of your last dose, or blood tests show high drug level.
- If you can become pregnant, you must have a documented negative pregnancy test before starting.
- You should not have life expectancy under 30 days (even with best care).
- You must not have certain recent clotting/bleeding emergencies, major active bleeding, or serious blood count problems (like very low platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called VMX-C001 to quickly reverse the effects of certain blood thinners (Factor Xa inhibitors) in people who need urgent surgery with a high risk of bleeding. It compares VMX-C001 to standard care to see which is more effective at helping blood clot normally.
This study looks at Ondexxya, a medicine used to reverse the effect of certain blood thinners during a dangerous bleeding emergency. It may help doctors better understand how to manage life-threatening bleeding caused by apixaban, rivaroxaban, or edoxaban.
This trial tests a clot-busting drug (thrombolysis) for people who had a stroke while on a Factor Xa inhibitor blood thinner. It aims to see if the drug can still safely break up the clot and reduce disability.
This study looks at how to safely manage your blood thinner (DOAC) around the time of a planned, high-bleed-risk surgery or procedure involving a spinal needle. The goal is to find the best way to stop and restart your medication to prevent bleeding and clotting problems.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
Hear when a new Coagulation Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.